|
Jun 9
|
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
|
|
Feb 14
|
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
|
|
Feb 11
|
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
|